CoChat

KEYNOTE-164: Pembrolizumab for patients with advanced microsatellite instability high (MSI-H) colorectal cancer.

Le, Dung T., Kavan, Petr, Kim, Tae Won, Burge, Matthew E., Van Cutsem, Eric, Hara, Hiroki, Boland, Patrick McKay, Van Laethem, Jean-Luc, Geva, Ravit, Taniguchi, Hiroya, Crocenzi, Todd S., Sharma, Manish, Atreya, Chloe Evelyn, Diaz, Luis A., Liang, Li Wen, Marinello, Patricia, Dai, Tong, O'Neil, Bert H. · 2018 · Journal of Clinical Oncology
Cited by 85

The DOI matches its Crossref record.

Abstract

3514 Background: Pembrolizumab is approved for the treatment of adult and pediatric patients (pts) with previously treated MSI-H cancer regardless of tumor type or site. This approval was based in part on data from cohort A of the phase 2 KEYNOTE-164 (NCT02460198) study of pts with MSI-H CRC after ≥2 prior lines of therapy including fluoropyrimidine, oxaliplatin, and irinotecan. In addition, in Cohort B of KEYNOTE-164, we evaluated the activity of pembrolizumab in pts with metastatic MSI-H CRC treated with ≥1 prior line of therapy. Methods: KEYNOTE-164 cohort B enrolled pts with metastatic CRC, MSI-H status confirmed locally by IHC or PCR, and ≥1 prior line of therapy (fluoropyrimidine, oxaliplatin, irinotecan, or anti VEGF/EGFR). Eligible pts received pembrolizumab 200 mg Q3W for 2 years or until progression, unacceptable toxicity, or withdrawal of consent. Tumor response was assessed Q9W per RECIST v1.1 by independent review. The primary endpoint was ORR. Secondary endpoints included DOR, PFS, OS, and safety. Results: Of 63 pts enrolled, median age (range) was 59 years (23-83), and 52% were male. Pts had a median of 2 prior therapies, and 94% had ≥1 prior therapy for advanced disease. As of Sep 12, 2017, median (range) duration of follow-up was 12.6 months (0.1-15.4). ORR was 32% (95% CI, 21-45) with 2 CRs and 18 PRs. Median DOR was not reached (NR); 95% of responses were ongoing with DOR ≥6 mo in 75% of responders. Median PFS was 4.1 month (95% CI, 2.1-NR) with a 12-month PFS rate of 41%. Median OS was NR with a 12-month OS rate of 76%. Forty (64%) pts had any grade treatment-related AEs, most commonly (≥10%) fatigue (18%), hypothyroidism (16%), and hyperthyroidism (11%); 7 (11%) pts had grade 3-4 treatment-related AEs of anemia, thrombocytopenia, diarrhea, pneumatosis intestinalis, arthritis, syncope, pneumonitis, and vasculitis (n = 1 each). There were no treatment-related deaths. Twenty (32%) pts had any grade immune-mediated AEs; 2 (3%) pts had grade 3-4 immune-mediated AEs of colitis and pneumonitis (n = 1 each). Conclusions: Pembrolizumab provided durable antitumor activity with a manageable safety profile in patients with MSI-H CRC that progressed after ≥1 prior line of therapy. Clinical trial information: NCT02460198.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2018.36.15_suppl.3514

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 85

Metadata

Authors
Le, D. T., Kavan, P., Kim, T. W., Burge, M. E., Van Cutsem, E., Hara, H., Boland, P. M., Van Laethem, J.-L., Geva, R., Taniguchi, H., Crocenzi, T. S., Sharma, M., Atreya, C. E., Diaz, L. A., Liang, L. W., Marinello, P., Dai, T., & O'Neil, B. H.
Venue
Journal of Clinical Oncology
Published
2018-05-20
Volume
36
Issue
15_suppl
Pages
3514-3514
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2891243575
Cited by
85
References
0
Type
conference abstract
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: KEYNOTE-164: Pembrolizumab for patients with advanced microsatellite instability high (MSI-H) colorectal cancer. https://app.cochat.ai/papers/10.1200/jco.2018.36.15_suppl.3514
The paper
Le, D. T., Kavan, P., Kim, T. W., Burge, M. E., Van Cutsem, E., Hara, H., Boland, P. M., Van Laethem, J.-L., Geva, R., Taniguchi, H., Crocenzi, T. S., Sharma, M., Atreya, C. E., Diaz, L. A., Liang, L. W., Marinello, P., Dai, T., & O'Neil, B. H. (2018). KEYNOTE-164: Pembrolizumab for patients with advanced microsatellite instability high (MSI-H) colorectal cancer. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2018.36.15_suppl.3514

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.